Proliferative glomerulonephritis
MONDO:0003134A constellation of renal disorders characterized by an increase number of cells in the glomerulus; these disorders generally present with nephrotic syndrome, and generally progress to end stage renal failure over a matter of weeks to years, depending on the etiology. Examples include IgA nephropathy, membranoproliferative glomerulonephritis, and rapidly progressive glomerulonephritis.
5 clinical trials for this condition and its sub-types, 1 tagged with Proliferative glomerulonephritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Proliferative glomerulonephritis
-
Acute proliferative glomerulonephritis 0 trials · 1 incl. sub-types
1 sub-type
- Crescentic glomerulonephritis 1 trial
-
Experimental cell therapy targets kidney disease
Disease control Not yet recruitingThis early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
A simple blood test may reveal kidney damage in lupus — no biopsy needed?
Diagnosis Not yet recruitingThis study asks whether levels of uromodulin, a protein in the blood, can indicate the severity of kidney damage in people with lupus nephritis. Researchers will compare uromodulin levels with kidney biopsy results from 90 participants, including those with different classes of l…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Can we predict kidney Disease's return after a transplant?
Knowledge-focused Not yet recruitingThis study follows 300 adults in China who have had a kidney transplant due to glomerulonephritis (GN), a type of kidney disease. The goal is to see how often GN comes back after the transplant and what factors might influence that. Participants will be monitored for three years …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC